Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUM-102
- Development stage
- Unknown
- Lead developer
- Sumaya Biotech
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SUM-102 (also known as Ad6-MSP-1) is an adenovirus serotype 6 (Ad6) vector-based vaccine candidate developed by Sumaya Biotech for the prevention of malaria caused by *Plasmodium falciparum*. The vaccine utilizes a non-replicating adenovirus vector to deliver the genetic sequence for the full-length Merozoite Surface Protein 1 (MSP1), a major antigen found on the surface of the malaria parasite during its blood stage. SUM-102 is designed to induce both cellular and humoral immune responses against the liver and blood stages of the parasite. It is primarily intended for use in a heterologous prime-boost vaccination regimen alongside SUM-101 (a recombinant protein subunit vaccine), specifically targeting travelers to malaria-endemic regions in Africa.
- Other names
- Ad6-MSP1Ad-6-MSP1Ad 6-MSP1Sumaya Biotech-MSP1 adenovirus vector vaccine
02
Targets
MSP1 (Merozoite surface protein 1)
Beyond the preview
Go deeper on SUM-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUM-102.